Shailender Bhatia, MD
Shailender Bhatia, MD, is the director of the Melanoma and Renal Cancer Program at Fred Hutchinson Cancer Center, and a professor of medical oncology at the University of Washington in Seattle, WA. Dr. Bhatia received his MBBS (equivalent to MD) degree at the All India Institute of Medical Sciences (AIIMS) in New Delhi, India and completed his internal medicine internship and residency at the University of Connecticut Health Center in Farmington, CT. He then completed his post-doctoral fellowship in hematology/oncology at the University of Washington and Fred Hutchinson Cancer Research Center (now Fred Hutchinson Cancer Center) in Seattle, WA.
Dr. Bhatia’s research interests include melanoma, Merkel cell carcinoma, non-melanoma skin cancers, immunotherapy, intratumoral therapy, and targeted therapy. Dr. Bhatia has co-authored numerous articles in top-tier peer-reviewed journals, including NEJM, Cell, JAMA, Lancet, JCO, Lancet Oncol, JAMA Oncol, JNCI, CCR, JITC, and others. He is an active member of the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and Society of Immunotherapy of Cancer (SITC).
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:4SCTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AgenusTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AmphivenaTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/11/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Bristol Meyers SquibbTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Regeneron (fka Checkmate Pharmaceuticals)Topic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:EMD SeronoTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ExicureTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:12/31/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Immune DesignTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:11/26/2021
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:IncyteTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Kuni FoundationTopic:Research fundingDate added:03/09/2023Date updated:02/13/2024Relationship end date:03/10/2025